Medifast (MED) Projected to Announce Earnings on Monday

Medifast (NYSE:MED) is projected to issue its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Medifast to post earnings of ($0.67) per share and revenue of $72.70 million for the quarter. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.36. The business had revenue of $76.04 million for the quarter, compared to analysts’ expectations of $69.20 million. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%. On average, analysts expect Medifast to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Medifast Trading Down 0.3%

Shares of NYSE MED opened at $9.65 on Monday. Medifast has a 12-month low of $9.22 and a 12-month high of $15.20. The company has a market cap of $107.30 million, a price-to-earnings ratio of -5.27 and a beta of 0.65. The stock’s 50 day simple moving average is $11.38 and its 200 day simple moving average is $11.10.

Insider Buying and Selling at Medifast

In other news, Director Scott Schlackman bought 2,500 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $12.53 per share, with a total value of $31,325.00. Following the completion of the transaction, the director directly owned 30,549 shares in the company, valued at approximately $382,778.97. The trade was a 8.91% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.70% of the stock is owned by company insiders.

Institutional Trading of Medifast

A number of hedge funds have recently made changes to their positions in MED. Charles Schwab Investment Management Inc. lifted its stake in Medifast by 30.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after acquiring an additional 181,618 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Medifast by 14.2% during the 3rd quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock worth $6,186,000 after purchasing an additional 56,174 shares during the last quarter. Lido Advisors LLC bought a new position in shares of Medifast during the 3rd quarter valued at $4,521,000. Dimensional Fund Advisors LP raised its holdings in shares of Medifast by 9.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 326,240 shares of the specialty retailer’s stock valued at $3,484,000 after purchasing an additional 27,871 shares in the last quarter. Finally, Steamboat Capital Partners LLC bought a new position in shares of Medifast during the 4th quarter valued at $2,952,000. 95.51% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MED has been the subject of a number of recent analyst reports. Weiss Ratings lowered Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Zacks Research raised Medifast from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $12.00.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.